Dynamic Optical Coherence Tomography(D-OCT) Aging Study: A Preliminary Evaluation of Structural Differences Between Young and Aged Skin, Cellulite and Atrophic Acne Scars in Female Caucasian Subjects With Fitzpatrick Skin Types I-III Utilizing Non-invasive in Vivo D-OCT.
- Conditions
- Skin Care
- Interventions
- Device: Skin ImagingOther: Facial Cleanser
- Registration Number
- NCT03767400
- Lead Sponsor
- Allergan
- Brief Summary
This single-center clinical study is being conducted over the course of 2 weeks to conduct an exploratory pilot study as a preliminary evaluation of D-OCT's ability to measure skin changes from aging. Assess structural differences between young and aged skin on the face. To identify the structural characteristics of atrophic acne scars relative to normal skin on the face. To explore characteristics of cellulite relative to normal skin on the thigh in young and aged skin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 99
-
Female Caucasian subjects with Fitzpatrick skin types I-III that meet one of the criteria listed below:
- Ages 18-30 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
- Ages 55-75 years old without acne scars on the face with or without visible cellulite on posterior thigh, or
- Ages 18-75 years old with atrophic acne scars
-
Subject has completed an appropriately administered informed consent process which includes signing the IRB approved consent form.
-
Good general health and free of any disease state or physical condition (e.g. psoriasis, rosacea, scars, tattoos etc.) which, in the investigator's opinion, might impair evaluations of the test sites or expose the subject to an unacceptable risk by study participation.
-
Willingness to remove all makeup on the day of the visit. Makeup may be applied after the study visit has been completed.
-
Willingness to cleanse their face and remove all face makeup at each scheduled clinic visit. No other topical products should be applied to the face until the study visit has been completed.
i. For cellulite subgroup, willingness to have thigh cleansed at each scheduled clinic visit.
-
Willingness to have investigator exams, skin instrumentation measurements, and digital photos performed on the face and/or thigh (for cellulite subgroup).
-
Women of childbearing potential must not be pregnant at the time of the study.
-
Has any condition that, in the opinion of the investigator, would make it unsafe for the subject to participate in the study or interfere with their clinical assessments (including conditions that require the concurrent use of anticoagulants, bleeding coagulopathies, photosensitivity diseases).
-
Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, tattoos, or other skin conditions in the test areas that would interfere with the assessments of this study.
-
Individuals who are pregnant.
-
Uncontrolled disease such as diabetes, hypertension, hyper or hypo-thyroidism, active hepatitis, immune deficiency, or autoimmune.
-
Individuals who have a pre-existing or dormant dermatologic condition (e.g. history of severe psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)
-
Individuals who have routinely used any of the following topical products, prescription products, or had any of the listed treatments/procedures within the listed time frame prior to study entry or will use during study:
- Any product that the investigator deems that could affect the study objectives. These include products that address skin imperfections. This does not include a basic cleanser, moisturizer and sunscreen.(time frame 2 weeks)
- Chemical peel, microdermabrasion, dermaplaning, or microneedling (time frame 3 months)
- Retin-A®, Retin-A Micro®, Renova®, Avita®, Tazorac®, Avage® or Differin® or other similar prescription drugs (time frame 3 months)
- Cosmetic injections (filler and/or toxins, i.e. Juvederm, Radiesse, Botox, etc.), non-ablative laser or fractional laser resurfacing (time frame 12 months)
- Accutane® or other oral retinoid, Ablative procedures (i.e. laser, chemical) (time frame 12 months)
-
Individuals who have any planned surgeries or procedures during the study.
-
Individuals who participated in a facial usage study within the last 30 days, or who are currently participating on another usage study.
-
Individuals currently on or planning to participate on any type of research study at another facility or a doctor's office during this study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group B - Aged skin (55 - 75 years old) Skin Imaging Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured. Group C - Atrophic acne scars (18 - 75 years old) Facial Cleanser Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured. Group C - Atrophic acne scars (18 - 75 years old) Skin Imaging Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured. Group A - Young skin (18 - 30 years old) Facial Cleanser Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured. Group B - Aged skin (55 - 75 years old) Facial Cleanser Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured. Group A - Young skin (18 - 30 years old) Skin Imaging Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
- Primary Outcome Measures
Name Time Method VivoSight software measurements of Epidermal Thickness Day 1 Epidermal thickness will be measured in microns.
VivoSight software measurements of surface roughness Day 1 Surface roughness measurements (Ra, Rq, Rz) will be measured in microns.
VivoSight software measurements of redness Day 1 Redness will be measured in percent
VivoSight software measurements of attenuation coefficient Day 1 Attenuation coefficient will be measured in AU (arbitrary unit)
- Secondary Outcome Measures
Name Time Method Overall Appearance of Fine Lines/Wrinkles Cheek Areas Day 1 The investigator will assess the participant's appearance of fine lines/wrinkles using a 5-point scale from (0=None to 4=Diffuse).
Blinded Independent Physician Assessor Grading of the D-OCT Images of Dermoepidermal Contrast Day 1 Grading (0 = absent to 3 = high).
Post-study D-OCT Image Analysis of Density and Attenuation Coefficient of Epidermis Day 1 Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert.
Overall Photodamage Score at Day 1 Day 1 The Investigator will assess the participant's overall photodamage using a 10-point scale where (0) = None to (9) = Severe).
Post-study D-OCT Image Analysis of Collagen Fibers Day 1 Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert. Measured as normal or in bundles.
Post-study D-OCT Image Analysis of Integrity of Collagen Day 1 Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert. Measure as (few, moderate, or many fragments).
Post-study D-OCT Image Analysis of Score of Vessels Day 1 Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert. Measured at 300 and 500 microns.
Post-study D-OCT Image Analysis of Vascularity Quantification with Thresholds Day 1 Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert. Measured at 300 and 500 microns depth.
Blinded Independent Physician Assessor Grading of the D-OCT Images of Stratum Corneum Reflectivity Day 1 Grading (0 = absent to 3 = high).
Blinded Independent Physician Assessor Grading of the D-OCT images of Upper Dermal Reflectivity Day 1 Grading (0 = absent to 3 = high).
Post-study Dynamic Optical Coherence Tomography (D-OCT) Image Analysis of Epidermal Thickness Day 1 Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert.
Post-study D-OCT Image Analysis of Density and Attenuation Coefficient of Superficial Dermis Day 1 Post-study D-OCT image analysis will be done (at the sponsor's discretion) by an independent physician expert.
Blinded Independent Physician Assessor Grading of the D-OCT images of Vessel Density Day 1 Grading (0 = no vessels to 3 = many vessels).
Antera 3D Images Day 1 The investigator will capture 3D images utilizing the Antera 3D.
VISIA-CR Images Day 1 The investigator will capture standardized digital photographs utilizing the VISIA-CR.
Trial Locations
- Locations (1)
Skinmedica Clinical Research and Innovation Center
🇺🇸Irvine, California, United States